Pirfenidone for idiopathic pulmonary fibrosis
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), an oral agent whose exact mechanism of action is unknown but is proposed to have antioxidant, anti-inflammatory and antifibrotic actions perhaps by its antagonism of the effects of tumor necrosis factor α (TNF-α), transforming growth factor β1 (TGFβ1) and interference in the p38 profibrotic pathway [16,17].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [16]
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationPirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Fibrotic Idiopathic Interstitial Pneumonia: The Prognostic Value of Longitudinal Functional Trends
Latsi, P. I., du Bois, R. M., Nicholson, A. G., Colby, T. V., Bisirtzoglou, D., Nikolakopoulou, A., Veeraraghavan, S., Hansell, D. M., & Wells, A. U. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200210-1245oc · Cited by 583
RAGHU, G., CRAIG JOHNSON, W., LOCKHART, D., & MAGETO, Y. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.4.9805017 · Cited by 468
Bois, R. M. D., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201007-1179oc · Cited by 465
Epidemiology of interstitial lung diseases in Greece
Karakatsani, A., Papakosta, D., Rapti, A., Antoniou, K. M., Dimadi, M., Markopoulou, A., Latsi, P., Polychronopoulos, V., Birba, G., Ch, L., et al. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.03.001 · Cited by 208
Self-citationCurrent and future therapeutic approaches in idiopathic pulmonary fibrosis
Bouros, D. E., & Antoniou, K. M. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00145004 · Cited by 94
Self-citation
Cited by
Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial
Raghu, G., Million-Rousseau, R., Morganti, A., Perchenet, L., Behr, J., & the MUSIC Study Group (2013) · European Respiratory Journal · doi:10.1183/09031936.00104612 · Cited by 277
Tzouvelekis, A., Paspaliaris, V., Koliakos, G., Ntolios, P., Bouros, E., Oikonomou, A., Zissimopoulos, A., Boussios, N., Dardzinski, B., Gritzalis, D., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-171 · Cited by 255
Self-citationPulmonary Autotaxin Expression Contributes to the Pathogenesis of Pulmonary Fibrosis
Oikonomou, N., Mouratis, M.-A., Tzouvelekis, A., Kaffe, E., Valavanis, C., Vilaras, G., Karameris, A., Prestwich, G. D., Bouros, D., & Aidinis, V. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0004oc · Cited by 250
Self-citationJi, Y., Dou, Y.-N., Zhao, Q.-W., Zhang, J.-Z., Yang, Y., Wang, T., Xia, Y.-F., Dai, Y., & Wei, Z.-F. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.36 · Cited by 178
Ravassa, S., López, B., Treibel, T. A., José, G. S., Losada-Fuentenebro, B., Tapia, L., Bayés‐Genís, A., Díez, J., & González, A. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101194 · Cited by 152
Metadata
- Authors
- Bouros, D.
- Affiliations
- Democritus University of Thrace (GR)
- Corresponding author
- Bouros, Demosthenes
- ORCID
- Bouros, Demosthenes
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2011-05
- Volume
- 377
- Issue
- 9779
- Pages
- 1727-1729
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2091976584
- Cited by
- 58
- References
- 12
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 1 · 2017: 6 · 2016: 3 · 2015: 4 · 2014: 2 · 2013: 6 · 2012: 8
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, CAPACITY trial, forced vital capacity, progression-free survival, 6-minute walk test, drug safety and efficacy, antifibrotic therapy
- MeSH terms
- Anti-Inflammatory Agents, Non-Steroidal, Dose-Response Relationship, Drug, Europe, Exercise Test, Humans, Pyridones, Vital Capacity, Randomized Controlled Trials as Topic, Drug Approval, Clinical Trials, Phase III as Topic, Disease-Free Survival, Evidence-Based Medicine, Endpoint Determination, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pirfenidone for idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1016/s0140-6736(11)60546-1
- The paper
- Bouros, D. (2011). Pirfenidone for idiopathic pulmonary fibrosis. The Lancet. https://doi.org/10.1016/s0140-6736(11)60546-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.